| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
First case of ovarian Sertoli-Leydig cell tumor after an allogeneic hematopoietic stem cell transplantation for Hodgkin's disease
DOI: 10.1016/j.leukres.2012.04.012
We report on the case of a 16-year-old girl diagnosed in 2001 with Hodgkin's disease (HD), subtype nodular-sclerosing, Ann-Arbor classification Stage II A. She received standard chemotherapy with adri...
|
Salvatore Perrone,
Irene Pecorella,
Walter Barberi,
Veronica Valle,
Giovanni Fernando Torelli,
Fiammetta Natalino,
Caterina Mercanti,
Robin Foà,
Anna Paola Iori
et al.
|
Correspondence
(In Press Corrected Proof)
|
25 May 2012 |
|
Selective toxicity towards myelodysplastic hematopoietic progenitors – Another rationale for iron chelation in MDS
DOI: 10.1016/j.leukres.2012.04.030
The issue whether iron overload (IO) contributes to the pathophysiology of myelodysplastic syndrome (MDS) and therefore requires treatment, is still controversial. There is no question that patients w...
|
E. Fibach,
E.A. Rachmilewitz
|
Editorial
(In Press Corrected Proof)
|
25 May 2012 |
|
Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia
DOI: 10.1016/j.leukres.2012.05.001
Abstract: Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry i...
|
Guilin Tang,
Jeffrey L. Jorgensen,
Yi Zhou,
Ying Hu,
Marian Kersh,
Guillermo Garcia-Manero,
L. Jeffrey Medeiros,
Sa A. Wang
et al.
|
Full-length article
(In Press Corrected Proof)
|
25 May 2012 |
|
Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone
DOI: 10.1016/j.leukres.2012.04.029
To date, azacitidine (Vidaza®, Celgene Corporation, Summit, NJ) is the only agent that has been demonstrated to prolong overall survival versus conventional care regimens (24.5 vs 15.0 months, respect...
|
Antonio M. Almeida,
Francesca Pierdomenico
|
Correspondence
(In Press Corrected Proof)
|
24 May 2012 |
|
Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia
DOI: 10.1016/j.leukres.2012.04.031
T-prolymphocytic leukemia (T-PLL) is a rare and aggressive postthymic malignancy with distinctive clinical and morphologic features. The disease is rapidly progressive and is associated with a dismal ...
|
Hao Xiang Yong,
Yeh Ching Linn,
Kiat Hoe Ong,
Daryl Tan
|
Correspondence
(In Press Corrected Proof)
|
22 May 2012 |
|
Combined chemotherapy and ALA-based photodynamic therapy in leukemic murine cells
DOI: 10.1016/j.leukres.2012.04.027
Abstract: The effects of combined administration of doxorubicin (DOX) and vincristine (VCR), with 5-aminolevulinic acid photodynamic treatment (ALA-PDT), were analyzed in sensitive murine leukemic cel...
|
Berenice Diez,
Glenda Ernst,
María Julieta Teijo,
Alcira Batlle,
Silvia Hajos,
Haydée Fukuda
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 May 2012 |
|
Targeting cyclin D1 for high risk myelodysplastic syndromes
DOI: 10.1016/j.leukres.2012.04.023
Excessive intramedullary apoptosis, proliferation and genomic instability are hallmarks of bone marrow in myelodysplastic syndromes (MDS). In early 1990s, using a then novel colorimetric double labeli...
|
Suneel D. Mundle
|
Editorial
(In Press Corrected Proof)
|
21 May 2012 |
|
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
DOI: 10.1016/j.leukres.2012.04.024
Abstract: Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in o...
|
Michael Thorpe,
Ana Montalvão,
Francesca Pierdomenico,
Filipa Moita,
António Almeida
et al.
|
Short communication
(In Press Corrected Proof)
|
21 May 2012 |
|
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
DOI: 10.1016/j.leukres.2012.04.025
Abstract: We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at...
|
Virginia M. Klimek,
Emily K. Dolezal,
Michael T. Tees,
Sean M. Devlin,
Karen Stein,
Alejandro Romero,
Stephen D. Nimer
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results
DOI: 10.1016/j.leukres.2012.04.026
Abstract: The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cl...
|
Ida Franiak-Pietryga,
Henryk Maciejewski,
Dariusz Wolowiec,
Aleksandra Salagacka,
Jerzy Z. Blonski,
Agnieszka Janus,
Aleksandra Kotkowska,
Ewa Wawrzyniak,
Paolo Ghia,
Marek Mirowski,
Tadeusz Robak,
Anna Korycka-Wolowiec
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia
DOI: 10.1016/j.leukres.2012.04.018
Abstract: Somatic CBL mutations have been reported in a variety of myeloid neoplasms but are rare in acute lymphoblastic leukemia (ALL). We analyzed 77 samples from hematologic malignancies, identifyi...
|
Yuka Saito,
Yoko Aoki,
Hideki Muramatsu,
Hideki Makishima,
Jaroslaw P. Maciejewski,
Masue Imaizumi,
Takeshi Rikiishi,
Yoji Sasahara,
Shigeo Kure,
Tetsuya Niihori,
Shigeru Tsuchiya,
Seiji Kojima,
Yoichi Matsubara
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 May 2012 |
|
A novel prognosis of acute myeloid leukemia: AML-M2 complicate with thrombocythemia after complete remission
DOI: 10.1016/j.leukres.2012.04.011
In February 2008, a 79-year-old man was admitted into the hospital with a 3-month history of smothered cough and fatigue. The patient had obvious tender pain in the middle and lower sternum and crude ...
|
Yi-xin Chen,
Ying Li,
Ling-yan Zhang,
Bin Liu
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
A patient with acute megakaryoblastic leukaemia who achieved CRi after decitabine treatment
DOI: 10.1016/j.leukres.2012.04.013
Acute megakaryoblastic leukaemia (AML-M7) is a rare subtype of acute myeloid leukaemia (<5%), which was first described in 1931 by Von Boros and Koreny . It can occur in both adults and children. A...
|
Cong Lu,
Guangsheng He,
Song Jin,
Xuhui Zhang,
Xiaohui Hu,
Depei Wu,
Aining Sun,
Changgeng Ruan
et al.
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib
DOI: 10.1016/j.leukres.2012.04.019
Combination of BCR-ABL specific tyrosine kinase inhibitors (TKIs) with chemotherapy has demonstrated superior responses resulting in higher complete remission (CR) rates and lower toxicity in Ph-posit...
|
Pu Kuang,
Ting Liu,
Qi Huang,
Yuanxin Ye,
Bing Xiang,
Jie Huang,
Lei Diwu,
Yuchun Wang,
Wentong Meng,
Tian Dong,
Shengyong Yang,
Xiaojun Lu
et al.
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
PAX5-AUTS2: A recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia
DOI: 10.1016/j.leukres.2012.04.015
Abstract: PAX5 rearrangements resulting in the expression of fusion transcripts account for 2–3% of childhood B-cell precursor acute lymphoblastic leukemia. Most PAX5 fusions are rare and many of them...
|
Dagmar Denk,
Karin Nebral,
Jutta Bradtke,
Gertrud Pass,
Anja Möricke,
Andishe Attarbaschi,
Sabine Strehl
et al.
|
Short communication
(In Press Corrected Proof)
|
14 May 2012 |
|
Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: Treatment with alemtuzumab
DOI: 10.1016/j.leukres.2012.04.016
Paraneoplastic pemphigus (PNP) is a rare autoimmune mucocutaneous disease associated with neoplasia , most commonly B-cell lymphoproliferative diseases. The mechanism behind the general propensity for...
|
Maria Ekbäck,
Bertil Uggla
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
Erythroblastic sarcoma
DOI: 10.1016/j.leukres.2012.04.009
Myeloid sarcoma is a rare entity associated with acute myeloid leukemia (AML)/myelodysplasia (MDS) or myeloproliferative neoplasia (MPN). It can precede, occur concurrently or appear after the diagnos...
|
Andrew Riddle,
Brian Olsen
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
Proliferative monocyte frequency is associated with circulating monocyte prevalence
DOI: 10.1016/j.leukres.2012.04.014
Monocytes and macrophages are often described as having limited potential for proliferation, although a significant proportion of human monocyte-derived cells enter the cell cycle and divide in vitro ...
|
Felix I.L. Clanchy,
John A. Hamilton
|
Correspondence
(In Press Corrected Proof)
|
14 May 2012 |
|
Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia
DOI: 10.1016/j.leukres.2012.04.007
Abstract: Leukemic cells from AML patients can be differentiated to dendritic cells (DCs). Such DCs have potential for immunotherapy of patients. Blasts from 15 AML patients were differentiated into D...
|
Maryam Nourizadeh,
Farimah Masoumi,
Ali Memarian,
Kamran Alimoghaddam,
Seyed Mohammad Moazzeni,
Jamshid Hadjati
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
Erythropoietin: The swinging pendulum
DOI: 10.1016/j.leukres.2012.04.017
Abstract: Erythropoiesis stimulating agents (ESAs) have been used widely for anemic patients, especially those on dialysis and with cancer. However, reports have suggested shorter survival in erythrop...
|
Howard S. Oster,
Drorit Neumann,
Michael Hoffman,
Moshe Mittelman
|
Review article
(In Press Corrected Proof)
|
14 May 2012 |
|
Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis
DOI: 10.1016/j.leukres.2012.04.001
Abstract: We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials includ...
|
Yuki Kagoya,
Yasuhito Nannya,
Mineo Kurokawa
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
DOI: 10.1016/j.leukres.2012.04.021
Abstract: The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN) who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor. Although allo...
|
Chad Cherington,
James L. Slack,
Jose Leis,
Roberta H. Adams,
Craig B. Reeder,
Joseph R. Mikhael,
John Camoriano,
Pierre Noel,
Veena Fauble,
Jeffrey Betcher,
Meagan S. Higgins,
Ginger Gillette-Kent,
Lisa D. Tremblay,
Mary E. Peterson,
Jane J. Olsen,
Raoul Tibes,
Ruben A. Mesa
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
ETV6 fusion genes in hematological malignancies: A review
DOI: 10.1016/j.leukres.2012.04.010
Abstract: Translocations involving band 12p13 are one of the most commonly observed chromosomal abnormalities in human leukemia and myelodysplastic syndrome. Their frequently result in rearrangements ...
|
Etienne De Braekeleer,
Nathalie Douet-Guilbert,
Frédéric Morel,
Marie-Josée Le Bris,
Audrey Basinko,
Marc De Braekeleer
et al.
|
Review article
(In Press Corrected Proof)
|
14 May 2012 |
|
Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry
DOI: 10.1016/j.leukres.2012.04.006
Abstract: MDS patients are prone to develop transfusional iron overload. Iron overload may partly explain why transfusion dependency is associated with a decreased likelihood of survival. Our matched-...
|
Judith Neukirchen,
Frank Fox,
Andrea Kündgen,
Kathrin Nachtkamp,
Corinna Strupp,
Rainer Haas,
Ulrich Germing,
Norbert Gattermann
et al.
|
Full-length article
(In Press Corrected Proof)
|
08 May 2012 |
|
Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia
DOI: 10.1016/j.leukres.2012.04.005
Abstract: We analyzed minimal residual disease (MRD) by multidimensional flow cytometry (MFC) after allogeneic stem cell transplantation in 41 patients with acute myeloid leukemia (AML) (n=31) or acut...
|
Takuya Miyazaki,
Hiroyuki Fujita,
Katsumichi Fujimaki,
Takeshi Hosoyama,
Reina Watanabe,
Takayoshi Tachibana,
Atsuko Fujita,
Kenji Matsumoto,
Masatsugu Tanaka,
Hideyuki Koharazawa,
Jun Taguchi,
Naoto Tomita,
Rika Sakai,
Shin Fujisawa,
Heiwa Kanamori,
Yoshiaki Ishigatsubo
et al.
|
Full-length article
(In Press Corrected Proof)
|
01 May 2012 |
|
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor
DOI: 10.1016/j.leukres.2012.03.025
Abstract: The advantage of Aurora kinase (AK) inhibitors in chronic myeloid leukemia (CML) therapy mostly arises from “off-target” effects on tyrosine kinase (TK) activity of wild type (wt) or mutated...
|
Manuela Mancini,
Elisa Leo,
Michela Aluigi,
Chiara Marcozzi,
Enrica Borsi,
Enza Barbieri,
Maria Alessandra Santucci
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
DOI: 10.1016/j.leukres.2012.04.002
Abstract: Background: We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplasti...
|
Matthew J. Olnes,
Aarthie Shenoy,
Barbara Weinstein,
Loretta Pfannes,
Kelsey Loeliger,
Zachary Tucker,
Xin Tian,
Minjung Kwak,
Francois Wilhelm,
Agnes S.M. Yong,
Irina Maric,
Manoj Maniar,
Phillip Scheinberg,
Jerome Groopman,
Neal S. Young,
Elaine M. Sloand
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group
DOI: 10.1016/j.leukres.2012.03.019
Abstract: The study of genetic lesions in AML cells is helpful to define the prognosis of patients with this disease. This study analyzed the frequency and clinical impact of recently described gene a...
|
J. Nomdedéu,
M. Hoyos,
M. Carricondo,
J. Esteve,
E. Bussaglia,
C. Estivill,
J.M. Ribera,
R. Duarte,
O. Salamero,
D. Gallardo,
C. Pedro,
A. Aventin,
S. Brunet,
J. Sierra
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors
DOI: 10.1016/j.leukres.2012.03.018
Abstract: We examined the effect of deferasirox (DFX) on CD34+ hematopoietic progenitors from MDS patients. Progressive, dose-dependent suppression of MDS progenitor proliferation in culture was obser...
|
Vinod Pullarkat,
Arjun Sehgal,
Liang Li,
Zhuo Meng,
Allen Lin,
Stephen Forman,
Ravi Bhatia
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 April 2012 |
|
Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma
DOI: 10.1016/j.leukres.2012.03.012
Abstract: B-cell activating factor (BAFF) is a B-cell growth factor. We measured its serum levels and correlated them with parameters of disease activity, as serum levels of tumor necrosis factor-α an...
|
M. Fragioudaki,
G. Tsirakis,
C.A. Pappa,
I. Aristeidou,
C. Tsioutis,
A. Alegakis,
D.S. Kyriakou,
E.N. Stathopoulos,
M.G. Alexandrakis
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 April 2012 |
|
A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure
DOI: 10.1016/j.leukres.2012.03.015
Abstract: The aim of this study was to evaluate the role of oxidative stress in the pathobiology of lymphoid leukaemias and its involvement in leukaemic relapse. For this purpose the generation of per...
|
Ana Bela Sarmento-Ribeiro,
Maria T. Proença,
Isabel Sousa,
Amélia Pereira,
Fátima Guedes,
Adriana Teixeira,
Catarina R. Oliveira
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 April 2012 |
|
Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia
DOI: 10.1016/j.leukres.2012.03.014
Abstract: This study was aimed to illustrate the significance of minimal residual disease (MRD) assessment on day 22 in childhood acute lymphoblastic leukemia. MRD were measured on day 22, day 36, wee...
|
Xiao-Jun Xu,
Yong-Min Tang,
Hong-Qiang Shen,
Hua Song,
Shi-Long Yang,
Shu-Wen Shi,
Wei-Qun Xu
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 April 2012 |
|
T-cell large granular lymphocytosis associated with malignant thymoma
DOI: 10.1016/j.leukres.2012.03.008
T-cell large granular lymphocytosis (T-LGL) is a proliferative disorder of CD3+ CD8+ T lymphocytes characterized by the clonal rearrangement of the T-cell receptor (TCR) and is consequently often term...
|
Amanda Herko,
Priyanka Pophali,
Paul K. Wallace,
Pritha Sharma,
Peter Loud,
Thaer Khoury,
Minoo Battiwalla
et al.
|
Correspondence
(In Press Corrected Proof)
|
04 April 2012 |
|
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
DOI: 10.1016/j.leukres.2012.03.003
Abstract: Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2V617F proteins. JAK2V617F has been recently shown to translocate to the nucleus and modify specific histones, thus...
|
Alfonso Quintás-Cardama,
Hagop Kantarjian,
Zeev Estrov,
Gautam Borthakur,
Jorge Cortes,
Srdan Verstovsek
et al.
|
Full-length article
(In Press Corrected Proof)
|
04 April 2012 |
|
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
DOI: 10.1016/j.leukres.2012.03.001
Abstract: DNA methylation and histone methylation are both involved in epigenetic regulation of gene expression and their dysregulation can play an important role in leukemogenesis. Aberrant DNA methy...
|
Richard L. Momparler,
Youssef Idaghdour,
Victor E. Marquez,
Louise F. Momparler
|
Full-length article
(In Press Corrected Proof)
|
03 April 2012 |
|
HDAC6 as a target for antileukemic drugs in acute myeloid leukemia
DOI: 10.1016/j.leukres.2012.02.026
Abstract: Inhibition of histone deacetylases (HDACs) by drugs such as vorinostat or depsipeptide has become treatment strategy under study in acute myeloid leukemia. Most preclinically and clinically ...
|
Björn Hackanson,
Leander Rimmele,
Marco Benkißer,
Mahmoud Abdelkarim,
Manfred Fliegauf,
Manfred Jung,
Michael Lübbert
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 March 2012 |
|
The venom of the spider Macrothele raveni induces apoptosis in the myelogenous leukemia K562 cell line
DOI: 10.1016/j.leukres.2012.02.025
Abstract: Spider venoms are a rich source of bioactive compounds with therapeutic potential. In traditional Chinese medicine, spiders and spider venoms have been used in the treatment of various ailme...
|
Zhonghua Liu,
Yan Zhao,
Jing Li,
Shiyan Xu,
Changjun Liu,
Yanghui Zhu,
Songping Liang
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
WITHDRAWN: Focal adhesion kinase comes into focus for B-cell acute lymphoblastic leukemia treatment
DOI: 10.1016/j.leukres.2010.12.007
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be foun...
|
Bu Yin
|
Retraction
(In Press Corrected Proof)
|
07 March 2011 |
|
WITHDRAWN: Therapeutic efficacy of focal adhesion kinase downregulation in REH cells by RNA interference
DOI: 10.1016/j.leukres.2010.12.002
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be foun...
|
Lu-Hong Xu,
Jian-Pei Fang,
Wen-Jun Weng,
Hong-Gui Xu,
Yi Le
et al.
|
Retraction
(In Press Corrected Proof)
|
07 March 2011 |